forecasted
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health · RFA-AG-28-009
See source for award amount
Not specified
For profit organizations other than small businesses, Small businesses, County governments, Public housing authorities/Indian housing authorities, State governments, Others (see text field entitled "Additional Information on Eligibility" for clarification), City or township governments, Native American tribal governments (Federally recognized), Special district governments, Independent school districts, Private institutions of higher education, Public and State controlled institutions of higher education, Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Geographic eligibility and all attachment-specific conditions require review of the original announcement.
Eligibility details
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
Matching funds & resources
Source matching-funds field: Not Required.
Matching funds and leveraged resources are different requirements. Read the description and reviewed rules below before determining resource commitments.
About this opportunity
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and Enable a precision medicine approach to AD drug development. The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Funding geography: Not specified — review source. A funder’s address does not establish eligibility.
Review original source ↗Funding instrument: Cooperative Agreement. Issuing jurisdiction: Federal. This is not a geographic eligibility determination.
Source fields and evidence
id: 363557
Source ↗ · id
opportunityNumber: RFA-AG-28-009
Source ↗ · opportunityNumber
opportunityTitle: Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Source ↗ · opportunityTitle
revision: 0
Source ↗ · revision
agencyDetails: {"code":"NIH","seed":"HHS-NIH11","agencyName":"National Institutes of Health","agencyCode":"HHS-NIH11","topAgencyCode":"HHS"}
Source ↗ · agencyDetails
owningAgencyCode: HHS-NIH11
Source ↗ · owningAgencyCode
cfdas: [{"id":435000,"opportunityId":363557,"cfdaNumber":"93.866","programTitle":"Aging Research"}]
Source ↗ · cfdas
forecastDesc: <p>The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.</p><p>Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to: </p><ul style="list-style-type:disc;"><li data-list-item-id="edaf28444d768130654e7d75ab0f53806">Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets; </li><li data-list-item-id="e7eae9f712fefc31506e1b9d5342b0cb1">Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and</li><li data-list-item-id="eed1f03a4a276200f88c528c3f0c1a919"> Enable a precision medicine approach to AD drug development. </li></ul><p>The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. </p>
Source ↗ · forecastDesc
applicantTypes: [{"id":"22","description":"For profit organizations other than small businesses"},{"id":"23","description":"Small businesses"},{"id":"01","description":"County governments"},{"id":"08","description":"Public housing authorities/Indian housing authorities"},{"id":"00","description":"State governments"},{"id":"25","description":"Others (see text field entitled \"Additional Information on Eligibility\" for clarification)"},{"id":"02","description":"City or township governments"},{"id":"07","description":"Native American tribal governments (Federally recognized)"},{"id":"04","description":"Special district governments"},{"id":"05","description":"Independent school districts"},{"id":"20","description":"Private institutions of higher education"},{"id":"06","description":"Public and State controlled institutions of higher education"},{"id":"12","description":"Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education"},{"id":"11","description":"Native American tribal organizations (other than Federally recognized tribal governments)"},{"id":"13","description":"Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education"}]
Source ↗ · applicantTypes
applicantEligibilityDesc: Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
Source ↗ · applicantEligibilityDesc
fundingInstruments: [{"id":"CA","description":"Cooperative Agreement"}]
Source ↗ · fundingInstruments
fundingActivityCategories: [{"id":"HL","description":"Health"}]
Source ↗ · fundingActivityCategories
costSharing: false
Source ↗ · costSharing
lastUpdatedDate: Aug 13, 2026 07:40:55 AM EDT
Source ↗ · lastUpdatedDate
status: forecasted
Source ↗ · oppHits[id=363557].oppStatus
Build your funding pipeline.
Save opportunities, filter by fit, and export your deadlines with membership.
View plans from $49/month ↗